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Objectives: In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma
(SC), was deﬁned, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this
histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a
series of translocation positive SC patients.
Patient and methods: We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch
head and neck centers. Subsequently, tumors with a morphological resemblance to SC were tested for the ETV6-
NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively diagnosed with SC were included. The
clinical characteristics and outcomes were retrieved from the patient ﬁles.
Results: Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age was
49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. One patient presented
with lymph node metastasis. All patients underwent tumor resection and 4 patients had a neck dissection. Four
patients had re-resection and 15 patients (48%) received postoperative radiotherapy. One patient developed a
local recurrence, no regional recurrences or distant metastases were observed. After a median follow-up of
49months the 5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%.
Conclusion: The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent
survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy,
does not seem to be indicated.
Introduction
Salivary gland cancers comprise a wide histological spectrum with
more than twenty diﬀerent subtypes [1]. In 2010, a new entity of
salivary gland cancer was described by Skálová et al., characterized by
the presence of the ETV6-NTRK3 fusion gene [2]. The histopathological
appearance resembles secretory carcinoma of the breast, and both tu-
mors share the ETV6-NTRK3 fusion gene, hence the proposed name was
mammary analogue secretory carcinoma (MASC). In the updated 2017
WHO classiﬁcation, MASC is acknowledged and referred to as ‘secretory
carcinoma’, to standardize nomenclature amongst diﬀerent organ sites
[1].
The morphological features of secretory carcinoma include a variety
of architectural growth patterns, intracytoplasmic vacuoles, lack of
intracytoplasmic zymogen granules in a mucinous or hemosiderin-
laden histiocyte-rich background [3]. Immunohistochemical markers
such as S100, vimentin, STAT5a, MUC4 and mammaglobin may be
helpful in preselecting patients with suspected secretory carcinoma, but
none of these markers can fully conﬁrm the diagnosis. However, the
presence of the ETV6-NTRK3 fusion gene is pathognomonic [4]. The
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most important entities in the diﬀerential diagnosis of secretory carci-
noma are acinic cell carcinoma (AciCC), polymorphous adenocarci-
noma (PAC), and adenocarcinoma not otherwise speciﬁed (NOS). Al-
though in salivary gland cancer the presence of the fusion gene is
speciﬁc for secretory carcinoma, the ETV6-NTRK3 fusion gene has also
been demonstrated in several other solid and hematological malig-
nancies, such as secretory carcinoma of the breast, papillary thyroid
carcinoma, congenital ﬁbrosarcoma, congenital mesoblastic nephroma,
acute myeloid leukemia and sino-nasal low-grade adenocarcinoma
[5–8].
In recent years, several reports have been published on character-
istic histopathological features of secretory carcinoma within the many
subtypes of SGC, but little is known about the clinical behavior of this
new entity, including the outcome of these patients. A review of 279
cases showed a male to female ratio of 1.5:1 and occurrence mostly
(68%) in the parotid gland [9]. Disease free survival (DFS) in secretory
carcinoma patients was reported to be similar to DFS in AciCC in a
comparison in respectively 29 and 38 patients [10]. The aim of the
current study is to focus on clinical behavior and outcome of patients
with secretory carcinoma.
Patients and methods
In four hospitals in the Netherlands, patients with subsets of salivary
gland cancer (AciCC, PAC and adenocarcinoma) were retrospectively
evaluated for morphological resemblance to secretory carcinoma by
pathologists (U.F, L.S, E.B. and S.M.W.) from 2000 until 2016. Patients
suspected of secretory carcinoma were tested for the presence of the
ETV6-NTRK3 fusion gene. The ETV6-NTRK3 fusion gene was analyzed
using reverse transcriptase-polymerase chain reaction (RT-PCR). RNA
was extracted from formalin-ﬁxed and paraﬃn-embedded tissues
(FFPE) using RNA-Bee-RNA isolation reagent (Bio-Connect BV, Huissen,
the Netherlands) according to standard procedures. RNA quantity and
quality were determined by NanoDrop measurement (Fisher Scientiﬁc,
Landsmeer, the Netherlands) and, subsequently, cDNA synthesis was
performed using Superscript II (Invitrogen Life Technologies Europe,
Bleiswijk, the Netherlands) and random hexamers (Promega Nederland,
Leiden, the Netherlands).
The cDNA was tested by the reverse transcription-polymerase chain
reaction (RT-PCR) for the HMBS (hydroxymethylbilase synthase)
housekeeping gene using the primers forw150 5′-TGCCAGAGAAGAGT
GTGGTG-3′, rev150 5′-ATGATGGCACTGAACTCCTG-3′, forw250 5′-
CTGGTAACGGCAATGCGGCT-3′, rev250 5′- TTCTTCTCCAGGGCATG
TTC-3′.
For detection of the ETV6-NTRK3 fusion, the following primers were
used: ETV6 forward primer P385: 5′-ACCACATCATGGTCTCTGTCT
CCC-3′and NTRK3 reverse primer P386: 5′-CAGTTCTCGCTTCAGCAC
GATG-3′. The PCR products were analyzed by agarose gel electro-
phoresis.
Patients who were prospectively diagnosed with secretory carci-
noma were also included. For both retrospective and prospective cases,
the presence of the ETV6-NTRK3 fusion gene was mandatory for in-
clusion in this study. Patients’ characteristics regarding clinical pre-
sentation, diagnosis, treatment and follow-up were collected by evalu-
ating medical records. According to the Dutch guidelines, review by a
medical ethical committee was not necessary due to the retrospective
nature of this study (www.federa.org).
Resection margins were categorized as free (> 5mm), close
(1–5mm) or involved (< 1mm) based on the pathology reports. For
further survival analysis, close and involved margins were grouped as
‘not free’.
For the prospectively collected cases the date of diagnosis was de-
ﬁned as ﬁrst date of histopathological conﬁrmation of the diagnosis
secretory carcinoma. In retrospective cases, the date of obtaining the
original histopathological material was used as date of diagnosis.
Statistics
Overall survival (OS) is deﬁned as the time from date of diagnosis
until date of death of any cause. Patients alive at the last known follow-
up date were censored. DFS is deﬁned as the time from date of surgery
until date of recurrence (local or regional recurrence or distant me-
tastasis) or death of any cause, whichever comes ﬁrst. Patients alive
without disease recurrence at last known follow-up were included in
the analysis as censored. OS and DFS were estimated using Kaplan
Meier survival curves. Statistical analysis was performed using SPSS
data analysis software version 22.0.
Results
Patients and tumor characteristics
In total, 42 patients were tested; 3 patients tested negative, for 6
patients the fusion gene could neither be conﬁrmed nor invalidated, in
33 patients we conﬁrmed the presence of the ETV6-NTRK3 fusion gene.
Unfortunately, clinical records were not available for 2 of the 33 con-
ﬁrmed patients; thus, a total of 31 patients with ETV6-NTRK3 fusion
gene positive secretory carcinoma were included. The median age at
diagnosis was 49 years (range 19–83 years), 17 patients (55%) were
male. Eighteen tumors (58%) were located in the parotid gland, one in
the submandibular gland, and the remaining 12 tumors in the minor
salivary glands. The primary site of the minor salivary gland tumors
were the lip (n=5), the oral mucosa (n=2), the soft palate (n=1),
the hard palate (n= 1) and the remaining three could not be further
speciﬁed. Nineteen patients (61%) had T1 tumors, 10 patients (32%) T2
tumors; for 2 patients the T-classiﬁcation was not available. Only one
patient presented with regional lymph node metastasis, none of the
patients had distant metastasis at diagnosis. In most patients, the pre-
senting symptom was a painless mass (22 patients). One patient pre-
sented with a painful swelling and one with a non-healing wound. For
the remaining 9 patients no symptoms could be retrieved from the
medical records. The median time from start of symptoms to diagnosis
was 14months (range 6 weeks–20 years).
Eleven patients were prospectively diagnosed with secretory carci-
noma between 2011 and 2016. The remaining 20 patients were retro-
spectively diagnosed with secretory carcinoma, conﬁrmed by the pre-
sence of the ETV6-NTRK3 fusion gene. The initial diagnosis of these
patients was between 2000 and 2012. Of these 20 patients, 16 patients
were previously diagnosed with AciCC, three as PAC and one as ade-
nocarcinoma NOS.
Baseline characteristics of all patients are shown in Table 1.
Primary treatment
Primary treatment for all 31 patients consisted of surgery.
Seventeen patients had a surgical resection of the aﬀected salivary
gland, and in four of them surgery also included a neck dissection (only
one patient had tumor positive lymph nodes). Eleven patients had ei-
ther a local excision, excision or incision biopsy of the tumor. For three
patients, the exact type of surgery could not be determined. Seven
patients (23%) had involved resection margins, nine patients had clo-
sely excised tumors (29%) and 13 (42%) had free resection margins. In
two patients, information about resection margins was not available.
Four patients (13%) had additional surgery, because of involved re-
section margins (2), a close excision margin (1) and an uncertain
margin after excision biopsy. Fifteen patients (48%) received post-
operative radiotherapy: all seven patients with involved resection
margins, six out of nine patients with closely excised tumors and two
patients with free resection margins. One of the patients with free re-
section margins had a diﬃcult preparation of the facial nerve during
surgery, and was therefore treated with postoperative radiotherapy. For
the other patient with free resection margins the exact reason for
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postoperative radiotherapy could not be retrieved from the patient ﬁles.
Of the four patients who underwent re-excision, two patients ad-
ditionally underwent postoperative radiotherapy. The characteristics of
patients with postoperative radiotherapy and patients with surgery only
are summarized in Table 2. The median dose of radiotherapy was 66 Gy
(range 60–66 Gy). More detailed information about the radiotherapy
target volume was available in eight out of 15 patients with radio-
therapy. In four patients, the target volume included the ipsilateral
neck; in the other four patients, only the surgical bed was irradiated.
None of the patients received chemotherapy.
Disease recurrence
Only one patient (4%) had a local recurrence, occurring 50months
after primary surgery (resection margins of the primary surgery were
not available), without postoperative radiotherapy. The patient re-
mained disease-free during the 40months following surgical resection
of the recurrence. None of the patients had a regional recurrence or
distant metastasis.
Survival
After a median follow up time of 49months, 1 patient died (without
Table 1
Patients’ and tumor characteristics.
Median age, in years [range] 49 [19–83]
Gender, n (%)
Male 17 (55)
Female 14 (45)
Tumor localization, n (%)
Major salivary glands
- Parotid 18 (58)
- Submandibular gland 1 (3)
- Sublingual gland 0 (0)
Minor salivary glands 12 (39)
Method of diagnosis of secretory carcinoma,
n (%)
Prospective 11 (35)
Retrospective
- Acinic cell carcinoma 16 (52)
- Polymorphous adenocarcinoma 3 (10)
- Adenocarcinoma, not otherwise speciﬁed 1 (3)
Signs and symptoms, n (%)
Painless mass 22 (71)
Painful mass 1 (3)
Non-healing wound 1 (3)
Unknown 7 (23)
Median duration of symptoms, (range) 14months (6 weeks–20 years)a
TNM stage, n
T1/T2/T3/T4/Tx 19/10/0/0/2
N0/N1/N2/N3 30/0/1/0
M0/M1 31/0
Surgery, n (%)
Yes 31 (1 0 0)
No 0 (0)
Resection margins, n (%)
Free (> 5mm) 13 (42)
Not Free
- Close (1–5mm) 9 (29)
- Involved (< 1mm) 7 (23)
Not available 2 (6)
Revision surgery, n (%)
Yes 4 (13)
No 27 (87)
Postoperative radiotherapy, n (%)
Yes 15 (48)
No 16 (57)
a Based on 20 patients.
Table 2
Characteristics of patients with secretory carcinoma with ETV6-NTRK3 fusion
gene mutation receiving postoperative radiotherapy versus patients with sur-
gery only.
Postoperative
radiotherapy
n=15
Surgery only
n=16
Median age, in years [range] 52 [20–83] 46 [19–68]
Gender, n (%)
Male 8 (53) 9 (56)
Female 7 (47) 7 (44)
Tumor localization, n (%)
Major salivary glands
Parotid 11 (73) 7 (44)
- Submandibular gland 1 (7) 0 (0)
- Sublingual gland 0 (0) 0 (0)
Minor salivary glands 3 (20) 9 (56)
Method of diagnosis of
secretory carcinoma, n
(%)
Prospective 5 (33) 6 (38)
Retrospective 10 (67) 10 (63)
- Acinic cell carcinoma 10 (67) 6 (38)
- Polymorphous
adenocarcinoma
0 (0) 3 (19)
- Adenocarcinoma, NOS 0 (0) 1 (6)
Signs and symptoms, n (%)
Painless mass 12 (80) 10 (63)
Painful mass 0 (0) 1 (6)
Non-healing wound 0 (0) 1 (6)
Unknown 3 (20) 4 (25)
Median duration of
symptoms, (range)
2 years (6
weeks–20 years)
6months (3
months–2 years)
TNM stadium, n
T1/T2/T3/T4/Tx 7/7/0/0/1 12/3/0/0/1
N0/N1/N2/N3 14/0/1/0 16/0/0/0
M0/M1 15/0/0/0 16/0/0/0
Surgery, n (%)
Yes 15 (100) 16 (100)
No 0 (0) 0 (0)
Resection margins, n (%)
Free (> 5mm) 2 (13) 11 (69)
Not Free
- Close (1–5mm) 6 (40) 3 (19)
- Involved (< 1mm) 7 (47) 0 (0)
Not available 0 (0) 2 (13)
Additional resection, (n%)
Yes 2 (13) 2 (13)
No 13 (87) 14 (87)
Fig. 1a. Overall survival of all secretory carcinoma patients.
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signs of disease recurrence). The estimated 5- and 10-year OS were
95%. The 5- and 10-year disease-free survival were 89%. OS and DFS
are displayed in Figs. 1a–1f.
The estimated 5-year OS and DFS were 89% for patients with free
resection margins, and 100% for patients with resection margins that
were not free (either close or involved), respectively.
The estimated 5-year OS and DFS of patients treated with surgery
and radiotherapy were both 89%, for patients treated with surgery only
these were 100% and 89%, respectively.
The OS and DFS for patients according to resection margins and
radiotherapy are also illustrated in Figs. 1a–1f.
Discussion
In this report of 31 patients with ETV6-NTRK3 fusion gene positive
secretory carcinoma, we presented the clinical spectrum of secretory
carcinoma. The outcome of disease was favorable and only one of the
patients had local recurrence of the disease.
There was a male to female ratio of 1.2:1, which is in accordance
with most reports showing a larger proportion of male patients. In a
literature review of 279 cases, the male to female ratio was 1.5:1 [9].
As for secretory carcinoma of the breast, in secretory carcinoma
pediatric cases may be encountered [11,12]. However, we had no pe-
diatric cases, but we did encounter 6 adolescent and young adults
(18–35 years).
We only observed T1 and T2 tumors in our cohort, although T3 and
T4 tumors were described by others [2,10]. Only one patient of our
series had cervical lymph node metastasis at time of diagnosis, and was
surgically treated. In another described series of 36 secretory carcinoma
patients, 18 patients had a neck dissection, of which 4 patients had
tumor positive lymph nodes [10].
In the current study, the largest proportion of retrospective cases of
secretory carcinoma were previously classiﬁed as AciCC and the re-
maining cases were mostly identiﬁed as PAC. AciCC was therefore the
most important diﬀerential diagnosis in this report. AciCC may be
morphologically diﬀerentiated by structural and cytologic diversity and
by the presence of large serous acinar cells containing zymogen gran-
ules which are absent in secretory carcinoma.
Remarkably, we found that 39% of tumors occurred in the minor
salivary glands. This is in agreement with data in the review of 279
secretory carcinoma patients [9]. In a Danish national cohort study 86/
Fig. 1b. Disease Free Survival all secretory carcinoma patients.
Fig. 1c. Overall survival categorized by resection margins being free or not
free.
Fig. 1d. Disease free survival categorized by resection margins being free or not
free.
Fig. 1e. Overall survival categorized by primary treatment with surgery versus
surgery and radiotherapy.
Fig. 1f. Disease free survival categorized by primary treatment with surgery
versus surgery and radiotherapy.
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97 (89%) of AciCCs presented in the parotid gland [13]. Secretory
carcinoma seems to be occurring more frequently outside the parotid
gland than AciCC. Therefore, if patients are diagnosed with a AciCC
located in the minor salivary glands there should be a suspicion of se-
cretory carcinoma.
Notably, eleven patients started with local excision, or incision
biopsies. Although the reasons were not entirely clear, this may possibly
be attributed to ambiguity on previous cytology or clinical appearance.
In this report, only one patient had a local recurrence 50months
after the primary treatment, which was successfully treated and re-
mained disease free during follow up. Distant metastasis did not occur
in our patients. However, it should be noted that one should be cautious
interpreting these data, as the median follow up time in this study is
only 49months, and given the low grade behavior of secretory carci-
noma, local recurrences might develop even after a more prolonged
period of follow up. Actually, patients have been described in the lit-
erature diagnosed with tumors with high grade transformation, in some
cases dying of disseminated disease within 2 and 6 years [14,15].
In the current study, the course of the disease is favorable in terms
of OS and DFS, and appears to be comparable to outcomes of AciCC.
However, it should be noted that morphologically high grade cases of
secretory carcinoma were not encountered. A survival analysis of 1353
cases AciCC based on the National Cancer Data Base (NCDB) in the
United States showed a 5-year overall survival of 83.3% and 5-year
disease speciﬁc survival of 91.4% [16].
Although clinical outcomes between patients with AciCC and PAC
versus secretory carcinoma may not diﬀer greatly, it is important to
distinguish secretory carcinoma patients from other salivary gland
cancers, mainly in the case of metastatic disease. The presence of the
NTRK-ETV6 fusion gene has revealed an actionable target and cur-
rently, a phase II trial with entrectenib is actively recruiting patients for
those patients harboring NTRK fusion genes. Entrectinib is an orally
available inhibitor of the tyrosine kinase tropomyosin-related kinases
(TRK) [17].
The role of adjuvant radiotherapy is controversial for AciCC. An
analysis of 1241 cases of parotid AciCC from the SEER database showed
no statistical diﬀerence in overall survival for patients with surgery
compared to patients undergoing surgery and adjuvant radiotherapy
[18]. It should however be noted that this is most likely confounding by
indication, with worst cases having received radiotherapy. In the cur-
rent series, 48 percent of patients received postoperative radiotherapy.
One could argue that the excellent outcomes of these secretory carci-
noma patients is due to the beneﬁcial eﬀects of the postoperative
radiotherapy or perhaps the intrinsic biological behavior of secretory
carcinoma. Due to the low number of events (either local recurrences
and/or death) and the diﬀerences in baseline characteristics, speciﬁ-
cally resection margins, our data should be interpreted with caution.
However, it is likely that patients with clinically N0 disease may be
spared from elective treatment, i.e. surgery or radiotherapy of the neck,
given the very low incidence of nodal metastases. Future research may
clarify the importance of adjuvant neck treatment for secretory carci-
noma.
The limitation of this study may be the selection of patients.
Secretory carcinoma has been recognized as a distinct entity of salivary
gland cancer since the association with the ETV6-NTRK3 fusion gene in
2010. Only a limited number of patients in the current series were di-
agnosed with secretory carcinoma prospectively. The other patients
were identiﬁed after reviewing the resection specimen of a subset of
salivary gland cancer and testing them for the presence of the ETV6-
NTRK3 fusion gene. Therefore, a selection bias may play a role in the
data as presented in this paper. Furthermore, due to the retrospective
nature of the study some cases had missing data.
However, with the presentation of 31 patients with conﬁrmed ETV6-
NTRK3 fusion gene secretory carcinoma and detailed data on the di-
agnosis, treatment and outcomes, we feel this makes these results give
more clinical background and a meaningful contribution to the existing
literature of secretory carcinoma.
Conclusion
We present the clinical course of 31 patients with ETV6-NTRK3
fusion gene conﬁrmed secretory carcinoma. The clinical course is fa-
vorable with a low rate of recurrences and an excellent overall and
disease free survival after a median follow up of 49months. Elective
treatment of the neck does not seem to be indicated considering the low
incidence of nodal metastases, good prognosis, and apparent low grade
behavior of secretory carcinoma.
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